Anthony Yartel

Anthony Yartel

Auto-generated profile, based on publicly available information

Anthony Yartel

Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention , Atlanta, GA 30333

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2013 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
RMRebecca L. Morgan
Rebecca L. Morgan
BBBrittney Baack
Brittney Baack
BSBryce D. Smith
Bryce D. Smith
AYAnthony Yartel
Anthony Yartel
MPMarc Pitasi
Marc Pitasi
YFYngve Falck-Ytter
Yngve Falck-Ytter
Background: Hepatitis C virus (HCV) is a leading cause of hepatocellular carcinoma (HCC). In the United States, this form of cancer occurs in approximately 15 000 persons annually. A systematic review of the evidence is needed to assess the benefits of treatment of HCV-infected persons on development of HCC. Purpose: To systematically review observational studies to determine the association between response to HCV therapy and development of HCC among persons at any stage of fibrosis and those with advanced liver disease. Data Sources: MEDLINE, EMBASE, CINAHL, the Cochrane Library, Web of Science, and the Database of Abstracts of Reviews and Effectiveness from inception through February 2012. Study Selection: English-language observational studies that compared therapy-derived sustained virologic response (SVR) with no response to therapy among HCV-infected persons, targeted an adult population, and had an average follow-up of at least 2 years. Data Extraction: Two investigators independently extracted data into uniform relative risk measures. The Grading of Recommendations Assessment, Development and Evaluation framework was used to determine the quality of the evidence. Data Synthesis: Thirty studies fulfilled the inclusion criteria, and 18 provided adjusted effect estimates that were used to calculate pooled relative risks. Among HCV-infected persons, SVR was associated with reduced risk for HCC (relative risk for all persons, 0.24 [95% CI, 0.18 to 0.31], moderate-quality evidence; advanced liver disease hazard ratio, 0.23 [CI, 0.16 to 0.35], moderate-quality evidence). Limitation: In the meta-analyses, some variables could not be controlled for because of the observational design of the included studies. Conclusion: Sustained virologic response after treatment among HCV-infected persons at any stage of fibrosis is associated with reduced HCC. The evidence was determined to be of moderate quality. Primary Funding Source: Centers for Disease Control and Prevention.

17 August 2012
Verified
Journal Article
Closed access
BSBryce D Smith
Bryce D Smith
RMRebecca L. Morgan
Rebecca L. Morgan
GBGeoff A Beckett
Geoff A Beckett
YFYngve Falck-Ytter
Yngve Falck-Ytter
DHDeborah Holtzman
Deborah Holtzman
JWJohn W Ward
John W Ward

1 March 2014 in American Journal of Public Health
Verified
Journal Article
Closed access
BSBryce D. Smith
Bryce D. Smith
GBGeoff A. Beckett
Geoff A. Beckett
AYAnthony Yartel
Anthony Yartel
DHDeborah Holtzman
Deborah Holtzman
NPNita Patel
Nita Patel
JWJohn W. Ward
John W. Ward
Objectives. We examined HCV exposure prevalence and predictors among persons in the United States born during 1945–1965. Methods. With data from the 1999–2008 National Health and Nutrition Examination Survey, we calculated the proportion of persons born during 1945–1965 who tested positive for HCV antibody (anti-HCV) and analyzed the prevalence by sociodemographic and behavioral risk factors. Results. Anti-HCV prevalence in the 1945–1965 birth cohort was 3.2% (95% confidence interval [CI] = 2.8%, 3.8%), substantially higher than among other adults (0.9%). Within the cohort, anti-HCV prevalence was higher among non-Hispanic Blacks (6.4%; 95% CI = 5.3%, 7.7%), persons with injection drug use histories (56.8%; 95% CI = 48.4%, 64.8%), and persons with elevated alanine aminotransferase levels (12.7%; 95% CI = 10.7%, 15.1%). Injection drug use (adjusted odds ratio = 98.4; 95% CI = 58.8, 164.5) was the strongest anti-HCV prevalence predictor. Among anti-HCV–positive persons, 57.8% reported having 2 or more alcoholic drinks daily. Conclusions. With the high prevalence of HCV among persons born during 1945–1965, the increasing morbidity and mortality associated with HCV, and reductions in liver cancer and HCV-related mortality when HCV is eradicated, it is critically important to identify persons with HCV and link them to appropriate care.

16 October 2013 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
BSBryce D. Smith
Bryce D. Smith
AJAmy Jewett
Amy Jewett
RBRichard D. Burt
Richard D. Burt
JZJon E. Zibbell
Jon E. Zibbell
AYAnthony K. Yartel
Anthony K. Yartel
EDElizabeth DiNenno
Elizabeth DiNenno
Background. Persons who inject drugs (PWID) are at high risk for acquiring hepatitis C virus (HCV) infection. The Centers for Disease Control and Prevention estimates there are 17 000 new infections per year, mainly among PWID. This study examines injection equipment serosorting—considering HCV serostatus when deciding whether and with whom to share injection equipment. Objective. To examine whether injection equipment serosorting is occurring among PWID in selected cities. Methods. Using data from the National HIV Behavioral Surveillance System-Injection Drug Users (NHBS-IDU2, 2009), we developed multivariate logistic regression models to examine the extent to which participants' self-reported HCV status is associated with their injection equipment serosorting behavior and knowledge of last injecting partner's HCV status. Results. Participants who knew their HCV status were more likely to know the HCV status of their last injecting partner, compared to those who did not know their status (HCV+: adjusted odds ratio [aOR] 4.1, 95% confidence interval [CI], 3.4–4.9; HCV−: aOR 2.5, 95% CI, 2.0–3.0). Participants who reported being HCV+, relative to those of unknown HCV status, were 5 times more likely to share injection equipment with a partner of HCV-positive status (aOR 4.8, 95% CI, 3.9–6.0). Conclusions. Our analysis suggests PWID are more likely to share injection equipment with persons of concordant HCV status.

23 September 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
AYAnthony K. Yartel
Anthony K. Yartel
DRDavid B. Rein
David B. Rein
KBKimberly Ann Brown
Kimberly Ann Brown
KKKatherine Krauskopf
Katherine Krauskopf
OMOmar I. Massoud
Omar I. Massoud
BSBryce D. Smith
Bryce D. Smith

1 September 2014 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
BSBryce D. Smith
Bryce D. Smith
AYAnthony K. Yartel
Anthony K. Yartel